<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937791</url>
  </required_header>
  <id_info>
    <org_study_id>190091</org_study_id>
    <secondary_id>19-C-0091</secondary_id>
    <nct_id>NCT03937791</nct_id>
  </id_info>
  <brief_title>Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions</brief_title>
  <official_title>A Phase II Study of Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Human papillomavirus (HPV) can cause vulvar high-grade squamous intraepithelial lesions&#xD;
      (HSIL). Sometimes, this can become cancer. Researchers want to see if T cell therapy can&#xD;
      treat vulvar HSIL. In this therapy, a person s immune cells are genetically modified so they&#xD;
      can attack the HPV.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test if a personalized immune treatment can cure vulvar HSIL.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      People ages 18 and older with vulvar HSIL that cannot be removed with surgery, or for which&#xD;
      surgery has failed&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with:&#xD;
&#xD;
      Medical history&#xD;
&#xD;
      Physical exam&#xD;
&#xD;
      HPV testing&#xD;
&#xD;
      Venous assessment&#xD;
&#xD;
      Chest x-ray&#xD;
&#xD;
      Heart and pulmonary tests&#xD;
&#xD;
      Participants will have a baseline visit. They may have a vulvar biopsy. Photographs will be&#xD;
      taken of their lesions.&#xD;
&#xD;
      Participants will have leukapheresis: Blood is removed from a needle in the arm and&#xD;
      circulated through a machine that takes out the white blood cells. The other blood cells are&#xD;
      returned through a needle in the other arm. The white blood cells will be used to grow&#xD;
      treatment cells.&#xD;
&#xD;
      Participants will receive the treatment through a tube inserted into an arm, neck, or chest&#xD;
      vein. They will recover in the hospital for 1 to 2 days. They will have blood tests and take&#xD;
      supportive medications.&#xD;
&#xD;
      Participants may have one more treatment.&#xD;
&#xD;
      Participants will have 5 follow-up visits in the first 3 months after treatment. They may&#xD;
      have more visits if their disease is growing. Visits will include blood tests. They may&#xD;
      include vulvar biopsies or leukapheresis.&#xD;
&#xD;
      Participants will have an annual physical exam for 5 years after treatment that can be done&#xD;
      at home or at the National Institutes of Health (NIH). Then they will have an annual phone or&#xD;
      email questionnaire for another 10 years....&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Vulvar high-grade squamous intraepithelial lesion (HSIL) is a premalignant epithelial&#xD;
           lesion that is frequently multifocal and/or recurrent.&#xD;
&#xD;
        -  The primary treatment is surgery, which may result in disfigurement and compromise of&#xD;
           the urethra, anus, or clitoris. Recurrence after surgery is common and primarily treated&#xD;
           with additional surgery.&#xD;
&#xD;
        -  Vulvar HSIL is caused by chronic infection with the human papillomavirus (HPV) type 16&#xD;
           infection. In this clinical trial the HPV-16 infection is targeted with a single&#xD;
           infusion of autologous T cells that have been genetically engineered to express a HPV-16&#xD;
           E7-specific T cell receptor (E7 TCR T cells).&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      -Determine the complete response rate for E7 TCR T cells in the treatment of vulvar HSIL.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Histologically confirmed diagnosis of HPV-16+ vulvar HSIL.&#xD;
&#xD;
        -  Expression of the human leukocyte antigen (HLA)-A2*02:01 allele.&#xD;
&#xD;
        -  Measurable lesion(s) that are recurrent or cannot be resected with acceptable cosmetic&#xD;
           or functional results.&#xD;
&#xD;
        -  Age greater than or equal to 18 years old.&#xD;
&#xD;
        -  Eastern Oncology Cooperative Group Performance Score of 0 or 1.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This is a phase II clinical trial&#xD;
&#xD;
        -  Simon minimax two-stage design with initial enrollment of 12 patients and expansion to&#xD;
           16 patients if one or more complete response(s) is/are observed in the initial patients.&#xD;
&#xD;
        -  Subjects will receive 1x10^11 E7 TCR T cells&#xD;
&#xD;
        -  No conditioning regimen or aldesleukin will be given&#xD;
&#xD;
        -  Re-enrollment will be allowed for a small number of subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    All analysis with identifiable specimens/data is complete or site has no identifiers linked to&#xD;
    the specimens/data. The one enrolled pt has been taken off study&#xD;
  </why_stopped>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Actual">June 22, 2020</completion_date>
  <primary_completion_date type="Actual">June 22, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fraction of Participants With Vulvar High-Grade Squamous Intraepithelial Lesions (HSIL) Who Experience a Complete Response for E7 T-Cell Receptor (TCR) T Cells Treatment</measure>
    <time_frame>3 months</time_frame>
    <description>The fraction of patients who experience a complete response. Complete Response is disappearance of all target lesions. No appearance of new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Grade 2 Adverse Events Unlikely Related to Drug in Participants Who Received E7 T-Cell Receptor (TCR) T Cells Administered in a Low Intensity Setting Without Conditioning or Systemic Aldesleukin</measure>
    <time_frame>30 days following the last dose of study therapy</time_frame>
    <description>Grade 2 adverse event is moderate.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 8 months and 6 days.</time_frame>
    <description>Here is the number of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Squamous Lntraepithelial Lesions of Vulva</condition>
  <condition>Neoplasms, Squamous Cell</condition>
  <condition>Vulvar HSIL</condition>
  <arm_group>
    <arm_group_label>Arm 1/1x10^11 E7 T Cell Receptor (TCR) T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>E7 T Cell Receptor (TCR)</intervention_name>
    <description>One dose of E7 TCR T cells (1x10^11 cells) will be administered intravenously over 20 to 30 minutes.</description>
    <arm_group_label>Arm 1/1x10^11 E7 T Cell Receptor (TCR) T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Patients must have vulvar High-Grade Squamous Intraepithelial Lesions (HSIL) as&#xD;
             confirmed by pathology report from a Clinical Laboratory Improvement Amendments&#xD;
             (CLIA)-certified laboratory.&#xD;
&#xD;
          -  Vulvar HSIL must be human papillomavirus (HPV)-16+ by a polymerase chain reaction&#xD;
             (PCR), Ribonucleic acid (RNA), or in situ hybridization test from a CLIA certified&#xD;
             laboratory.&#xD;
&#xD;
          -  Patients must have measurable lesion(s) as defined in one or more of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Failure of surgery to control disease (i.e. positive margins after surgery or&#xD;
                  recurrence of HSIL after surgery).&#xD;
&#xD;
               -  Multifocal or extensive disease for which surgery would result in disfigurement&#xD;
                  that is not be acceptable to the patient.&#xD;
&#xD;
               -  Disease for which surgery would have a risk of functional impairment that is not&#xD;
                  be acceptable to the patient (i.e. involve partial or complete excision of the&#xD;
                  clitoris, anus, vagina, or urethra).&#xD;
&#xD;
          -  Patients may have received any previous therapy, including surgical excision. Patients&#xD;
             with recurrent disease must have histologically documented recurrence on new biopsy&#xD;
             and a measurable lesion that meets the above criteria.&#xD;
&#xD;
          -  Patients must have the human leukocyte antigen (HLA)-A*02:01 allele&#xD;
&#xD;
          -  Age greater than or equal to18 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          -  Able to understand and sign the Informed Consent Document.&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative pregnancy test. Women of&#xD;
             child-bearing potential are defined as all women who are not post-menopausal or who&#xD;
             have not had a hysterectomy. Postmenopausal will be defined as women over the age of&#xD;
             55 who have not had a menstrual period in at least 1 year.&#xD;
&#xD;
          -  The effects of E7 T-Cell Receptor (TCR) T Cells on the developing human fetus are&#xD;
             unknown. For this reason, women of child-bearing potential must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry and for the duration of study participation. Should a woman become pregnant or&#xD;
             suspect she is pregnant while she is participating in this study, she should inform&#xD;
             her treating physician immediately.&#xD;
&#xD;
          -  Seronegative for human immunodeficiency virus (HIV) antibody. The experimental&#xD;
             treatment being evaluated in this protocol depends on an intact immune system.&#xD;
             Patients who are HIV seropositive can have decreased immune-competence and thus be&#xD;
             less responsive to the experimental treatment.&#xD;
&#xD;
          -  Seronegative for hepatitis B antigen and hepatitis C antibody. If hepatitis C antibody&#xD;
             test is positive, then the patient must be tested for the presence of antigen by&#xD;
             reverse transcription (RT)-PCR and be hepatitis C virus (HCV) RNA negative.&#xD;
&#xD;
          -  Must be willing to participate in Gene Therapy Long Term Followup Protocol&#xD;
             (20-C-0051), which will follow patients for up to 15 years per Food and Drug&#xD;
             Administration (FDA) requirements.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  leukocytes greater than or equal to 3,000/mcL&#xD;
&#xD;
               -  absolute neutrophil count greater than or equal to 1,000/mcL&#xD;
&#xD;
               -  platelets greater than or equal to 100,000/mcL&#xD;
&#xD;
               -  hemoglobin greater than or equal to 9.0 g/dL&#xD;
&#xD;
               -  total bilirubin within 1.5X normal institutional limits except in patients with&#xD;
                  Gilbert's Syndrome who must have a total bilirubin &lt; 3.0 mg/dL&#xD;
&#xD;
               -  Aspartate Aminotransferase (AST)/Serum glutamic-oxaloacetic&#xD;
                  transaminase(SGOT)/Alanine Aminotransferase (ALT)/Serum glutamic pyruvic&#xD;
                  transaminase,(SGPT) Serum ALT/AST &lt; 3X upper limit of normal (ULN)&#xD;
&#xD;
               -  creatinine &lt; 1.5X baseline, &lt; 1.5X ULN OR&#xD;
&#xD;
               -  creatinine clearance greater than or equal to 60 mL/min/1.73 m(2) for patients&#xD;
                  with creatinine levels above institutional normal (by the Chronic Kidney Disease&#xD;
                  Epidemiology Collaboration (CKD-EPI) equation)&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  Because there is an unknown but potential risk for adverse events in nursing infants&#xD;
             secondary to treatment of the mother with E7 TCR, breastfeeding should be discontinued&#xD;
             if the mother is treated with E7 TCR. These potential risks may also apply to other&#xD;
             agents used in this study.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, any ongoing or active&#xD;
             infection (e.g. requiring anti-infective therapy), coagulation disorders,&#xD;
             cardiovascular disorders, respiratory disorders, cancer, or psychiatric illness/social&#xD;
             situations (within the last six months) that would limit compliance with study&#xD;
             requirements.&#xD;
&#xD;
          -  Any form of systemic immunodeficiency, including acquired deficiency such as HIV or&#xD;
             primary immunodeficiency such as Severe Combined Immunodeficiency Disease. The&#xD;
             experimental treatment being evaluated in this protocol depends on an intact immune&#xD;
             system. Patients who have decreased immune competence maybe less responsive to the&#xD;
             treatment.&#xD;
&#xD;
          -  Concurrent systemic steroid therapy if greater than the equivalent of 5 mg prednisone&#xD;
             by mouth (PO) daily. Patients previously on steroids must be off steroids for four&#xD;
             weeks prior to treatment.&#xD;
&#xD;
          -  Cardiac stress test and pulmonary function tests maybe required for patients with a&#xD;
             clinical history of significat cardiopulmonary disease. Patients with active cardiac&#xD;
             ischemia or severe chronic obstructive pulmonary disease are not eligible.&#xD;
&#xD;
          -  Patients with any active invasive cancer are not eligible.&#xD;
&#xD;
          -  Patients with vulvar HSIL that is not HPV-16+ or is associated with multiple types of&#xD;
             high-risk HPV at the time of eligibility assessment are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Norberg, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2019-C-0091.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <results_first_submitted>February 24, 2021</results_first_submitted>
  <results_first_submitted_qc>February 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2021</results_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Scott Norberg, D.O.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Human Papilloma Virus (HPV) Type 16</keyword>
  <keyword>Retroviral Vector Supernatant</keyword>
  <keyword>Leukapheresis</keyword>
  <keyword>T Cell Receptor</keyword>
  <keyword>Premalignant Epithelial Lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03937791/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Cohort Screening Consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03937791/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Cohort Treatment Consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03937791/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells</title>
          <description>1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.&#xD;
E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10^11 cells) will be administered intravenously over 20 to 30 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells</title>
          <description>1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.&#xD;
E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10^11 cells) will be administered intravenously over 20 to 30 minutes.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fraction of Participants With Vulvar High-Grade Squamous Intraepithelial Lesions (HSIL) Who Experience a Complete Response for E7 T-Cell Receptor (TCR) T Cells Treatment</title>
        <description>The fraction of patients who experience a complete response. Complete Response is disappearance of all target lesions. No appearance of new lesions.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells</title>
            <description>1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.&#xD;
E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10^11 cells) will be administered intravenously over 20 to 30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Participants With Vulvar High-Grade Squamous Intraepithelial Lesions (HSIL) Who Experience a Complete Response for E7 T-Cell Receptor (TCR) T Cells Treatment</title>
          <description>The fraction of patients who experience a complete response. Complete Response is disappearance of all target lesions. No appearance of new lesions.</description>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Grade 2 Adverse Events Unlikely Related to Drug in Participants Who Received E7 T-Cell Receptor (TCR) T Cells Administered in a Low Intensity Setting Without Conditioning or Systemic Aldesleukin</title>
        <description>Grade 2 adverse event is moderate.</description>
        <time_frame>30 days following the last dose of study therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells</title>
            <description>1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.&#xD;
E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10^11 cells) will be administered intravenously over 20 to 30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Grade 2 Adverse Events Unlikely Related to Drug in Participants Who Received E7 T-Cell Receptor (TCR) T Cells Administered in a Low Intensity Setting Without Conditioning or Systemic Aldesleukin</title>
          <description>Grade 2 adverse event is moderate.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</title>
        <description>Here is the number of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 8 months and 6 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells</title>
            <description>1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.&#xD;
E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10^11 cells) will be administered intravenously over 20 to 30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)</title>
          <description>Here is the number of participants with non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 8 months and 6 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1/1x10^11 E7 T Cell Receptor (TCR) T Cells</title>
          <description>1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.&#xD;
E7 T Cell Receptor (TCR): One dose of E7 TCR T cells (1x10^11 cells) will be administered intravenously over 20 to 30 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Norberg, D.O.</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-275-9668</phone>
      <email>scott.norberg@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

